Curated News
By: NewsRamp Editorial Staff
May 21, 2026

SureNano Science Targets GLP-1 Obesity Market with Novel Peptide GEP-44

Discuss on Substack
Original Source

TLDR

  • SureNano Science's GEP-44 peptide could offer a competitive edge with improved tolerability and potential non-injectable delivery over blockbuster GLP-1 drugs.
  • SureNano acquired GlucaPharm for exclusive license to GEP-44, a patented peptide developed at Syracuse University, advancing through FDA pathway for obesity and metabolic disease.
  • SureNano's innovative GLP-1 therapy aims to improve obesity treatment with better tolerability, potentially enhancing quality of life for millions.
  • SureNano's GEP-44 peptide may enable non-injectable delivery, a novel approach that could transform how patients manage obesity and metabolic disorders.

Impact - Why it Matters

This news matters because the global obesity epidemic has created a massive demand for effective treatments, with GLP-1 therapies already reshaping the pharmaceutical landscape. SureNano's GEP-44, if successful, could offer a more tolerable and potentially non-injectable alternative to current blockbuster drugs, expanding access for patients who avoid injections. For investors, this represents an opportunity to back a small-cap company with a differentiated asset in a high-growth market, though risks remain in the early-stage development and regulatory pathway.

Summary

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, is strategically positioning itself in the rapidly growing GLP-1 therapy market, which includes blockbuster drugs like Ozempic®, Wegovy®, and Mounjaro®. Through its acquisition of GlucaPharm Inc., SureNano holds an exclusive license to develop GEP-44, a novel peptide discovered at Syracuse University, targeting obesity and metabolic disorders. GEP-44 is designed as a next-generation GLP-1 therapeutic with improved tolerability and potential non-injectable delivery, aiming to differentiate from current market leaders. The company is advancing the asset through the FDA pathway with the goal of entering clinical development.

SureNano Science is transitioning from its initial business of selling and distributing the SureNano™ surfactant—a food-grade compound for nanoemulsions—into a pharmaceutical-focused company. The surfactant, which enhances bioavailability, clarity, and taste, is exclusively licensed for distribution in Canada, Oklahoma, and Colorado. However, the core of its future lies in the GLP-1 pipeline, where it seeks to compete with major pharmaceutical players by offering a differentiated treatment option.

The news release, disseminated via BioMedWire (a brand within the Dynamic Brand Portfolio @ IBN), highlights SureNano's efforts to capture investor attention in the booming obesity drug market. For more details, readers can visit the full article at https://ibn.fm/cTKmO and the company’s newsroom at https://ibn.fm/SURNF. The release also promotes BioMedWire's services, including press release enhancement and social media distribution, to amplify corporate communications.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, SureNano Science Targets GLP-1 Obesity Market with Novel Peptide GEP-44

blockchain registration record for this content.